Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Hepatitis C 3Lymphoma, Non-Hodgkin 2Precancerous Conditions 1Melanoma 1Malignant Solid Tumor 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma 1Liver Neoplasms 1Liver Diseases 1Leukemia, Myeloid, Acute 1Infections 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Moxifloxacin 2Ciprofloxacin 2telaprevir 1peginterferon alfa-2a 1Voriconazole 1Ribavirin 1Negative-Pressure Wound Therapy 1Immunosuppression Therapy 1Diet 1Cone-Beam Computed Tomography 1Caspofungin 1Amoxicillin-Potassium Clavulanate Combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Infections × Ribavirin × Clear all
NCT01821963 2020-09-24

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

M.D. Anderson Cancer Center

Phase 3 Terminated
1 enrolled 3 charts
Gastrointestinal

Hepatitis C, Carcinoma, Hepatocellular, Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡